MCID: LNG035
MIFTS: 38

Lung Large Cell Carcinoma malady

Categories: Cancer diseases, Respiratory diseases, Rare diseases

Aliases & Classifications for Lung Large Cell Carcinoma

Aliases & Descriptions for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 12 14
Large Cell Carcinoma of Lung 12 69
Large Cell Lung Carcinoma 12
Large Cell Lung Cancer 52

Classifications:



External Ids:

Disease Ontology 12 DOID:4556
NCIt 47 C4450
SNOMED-CT 64 254629004
UMLS 69 C0345958

Summaries for Lung Large Cell Carcinoma

MalaCards based summary : Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to large cell carcinoma with rhabdoid phenotype and lung cancer. An important gene associated with Lung Large Cell Carcinoma is ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Akt Signaling and Actin Nucleation by ARP-WASP Complex. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include lung, and related phenotype is Decreased viability.

Wikipedia : 71 Large-cell carcinoma (LCC) is a heterogeneous group of undifferentiated malignant neoplasms that lack... more...

Related Diseases for Lung Large Cell Carcinoma

Diseases in the Lung Large Cell Carcinoma family:

Lung Clear Cell Carcinoma Small Cell Lung Cancer, Adult

Diseases related to Lung Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
id Related Disease Score Top Affiliating Genes
1 large cell carcinoma with rhabdoid phenotype 11.6
2 lung cancer 11.3
3 lung mixed small cell and squamous cell carcinoma 11.1
4 lung giant cell carcinoma 10.9
5 large cell carcinoma 10.2
6 thrombocytosis 9.6
7 gingivitis 9.6
8 large cell neuroendocrine carcinoma 9.6
9 dermatomyositis 9.6
10 calcinosis 9.6
11 inner ear disease 9.6
12 polyarteritis nodosa 9.6
13 autoimmune inner ear disease 9.6
14 granulomatous endometritis 8.1 ANKK1 BRSK1 BTK CDC42BPB DDR2 EPHA5

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:



Diseases related to Lung Large Cell Carcinoma

Symptoms & Phenotypes for Lung Large Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.09 MTOR
2 Decreased viability GR00173-A 11.09 ANKK1
3 Decreased viability GR00221-A-1 11.09 FGFR1 ROS1 WNK3 BRSK1 BTK DDR2
4 Decreased viability GR00221-A-2 11.09 FGFR1 ROS1 TTN ANKK1 WNK3 BRSK1
5 Decreased viability GR00221-A-3 11.09 BRSK1 BTK CDC42BPB EPHA5
6 Decreased viability GR00221-A-4 11.09 MTOR TTN ANKK1 WNK3 BRSK1 BTK
7 Decreased viability GR00301-A 11.09 BTK
8 Decreased viability GR00342-S-1 11.09 MTOR TTN ROS1
9 Decreased viability GR00342-S-2 11.09 MTOR
10 Decreased viability GR00342-S-3 11.09 EPHA5 TTN
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.34 TRRAP
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.34 TRRAP
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.34 WNK3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.34 MTOR
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.34 WNK3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.34 TRRAP
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.34 WNK3 TRRAP
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.34 MTOR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.34 BTK
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.34 TRRAP WNK3 BTK MTOR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.34 TRRAP
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.34 TRRAP
23 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.3 DDR2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.3 BTK
25 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.3 MTOR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.3 MTOR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.3 DDR2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.3 NME1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.3 WNK3
30 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.3 BTK
31 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.3 NME1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.3 BTK
33 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.3 BRSK1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.3 BTK
35 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.3 MTOR DDR2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.3 NME1 TRRAP
37 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.3 DDR2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.3 BRSK1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.3 TRRAP
40 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.3 DDR2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.3 TRRAP
42 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.3 BRSK1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.3 DDR2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.3 BTK WNK3
45 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.3 WNK3
46 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.3 DDR2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.3 BTK BRSK1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.3 MTOR
49 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.3 NME1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.3 WNK3
51 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.3 BRSK1
52 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.3 MTOR BTK
53 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.3 DDR2
54 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.3 MTOR NME1 TRRAP BTK WNK3 DDR2
55 Increased shRNA abundance (Z-score > 2) GR00366-A-97 10.3 NME1
56 Decreased substrate adherent cell growth GR00193-A-1 10.28 ROS1 BRSK1 BTK TTN
57 Decreased substrate adherent cell growth GR00193-A-2 10.28 MTOR ROS1 TRRAP WNK3
58 Decreased substrate adherent cell growth GR00193-A-4 10.28 BTK ANKK1 FGFR1
59 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 10 BRSK1 CDC42BPB FGFR1 MTOR NME1 TRRAP
60 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.95 WNK3 ANKK1 BRSK1 BTK MTOR TRRAP
61 Decreased vesicular stomatitis virus (VSV) infection GR00356-A-1 9.77 BRSK1 MTOR TRRAP TTN ANKK1
62 Increased cell viability after pRB stimulation GR00230-A-1 9.73 DDR2 WNK3 ANKK1 BRSK1 BTK CDC42BPB
63 Condensed cis-Golgi GR00365-A 9.69 FGFR1 ROS1 WNK3
64 Decreased cell proliferation GR00353-A 9.67 ANKK1 MTOR TRRAP
65 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 9.46 FGFR1 MTOR ROS1 TRRAP
66 Transferrin accumulation in the perinuclear area GR00356-A-3 8.8 FGFR1 MTOR TRRAP

Drugs & Therapeutics for Lung Large Cell Carcinoma

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 246)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
4
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
5
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
6
Everolimus Approved Phase 4,Phase 3,Phase 1 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
9
Armodafinil Approved, Investigational Phase 4 112111-43-0
10
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
12
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
13
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
16 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
17 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
23 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
25 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
27 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Central Nervous System Stimulants Phase 4
29 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 1
30 Wakefulness-Promoting Agents Phase 4
31 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
32 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
33
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
34
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
35
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1 216974-75-3
36
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
37
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
38
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
39
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
40
Vindesine Approved Phase 3 59917-39-4, 53643-48-4 40839
41
Captopril Approved Phase 3 62571-86-2 44093
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Irinotecan Approved, Investigational Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
44
Palivizumab Approved, Investigational Phase 3 188039-54-5
45
Ribavirin Approved Phase 3 36791-04-5 37542
46
Cetuximab Approved Phase 2, Phase 3, Phase 1 205923-56-4 56842117 2333
47
Doxorubicin Approved, Investigational Phase 2, Phase 3, Phase 1 23214-92-8 31703
48
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
49
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
50
Lenograstim Approved Phase 3,Phase 2 135968-09-1

Interventional clinical trials:

(show top 50) (show all 332)
id Name Status NCT ID Phase
1 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4
2 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
3 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4
4 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4
5 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Active, not recruiting NCT02151149 Phase 4
6 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3
7 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
8 ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Completed NCT00404924 Phase 3
9 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
10 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3
11 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
12 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3
13 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3
14 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3
15 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3
16 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3
17 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3
18 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3
19 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3
20 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3
21 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3
22 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3
23 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3
24 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3
25 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
26 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer Completed NCT00312377 Phase 3
27 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
28 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
29 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed NCT00045162 Phase 3
30 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
31 Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) Completed NCT00409188 Phase 3
32 A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) Completed NCT00257608 Phase 3
33 ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients Recruiting NCT02737501 Phase 3
34 Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy Recruiting NCT02004184 Phase 3
35 S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3
36 Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases Recruiting NCT02759783 Phase 2, Phase 3
37 S1400I Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting NCT02785952 Phase 3
38 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Recruiting NCT02438722 Phase 2, Phase 3
39 Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Recruiting NCT02201992 Phase 3
40 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Recruiting NCT01575548 Phase 3
41 Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Recruiting NCT02193282 Phase 3
42 Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer Recruiting NCT02595944 Phase 3
43 Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Recruiting NCT00632853 Phase 3
44 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3
45 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
46 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
47 Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy Recruiting NCT02445391 Phase 3
48 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3
49 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02488967 Phase 3
50 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3

Search NIH Clinical Center for Lung Large Cell Carcinoma

Genetic Tests for Lung Large Cell Carcinoma

Anatomical Context for Lung Large Cell Carcinoma

MalaCards organs/tissues related to Lung Large Cell Carcinoma:

39
Lung

Publications for Lung Large Cell Carcinoma

Articles related to Lung Large Cell Carcinoma:

id Title Authors Year
1
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. ( 25638031 )
2015
2
Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. ( 20077433 )
2010
3
Toona sinensis extracts induced cell cycle arrest and apoptosis in the human lung large cell carcinoma. ( 20123594 )
2010
4
Lung large cell carcinoma producing granulocyte-colony-stimulating factor. ( 17184692 )
2007
5
Primary lung large cell carcinoma metastatic to the vulva: a case report and review of the literature. ( 15350382 )
2004
6
Establishment and characterization of a cell line, KaMi, from human lung large cell carcinoma. ( 1279943 )
1992

Variations for Lung Large Cell Carcinoma

Cosmic variations for Lung Large Cell Carcinoma:

9 (show top 50) (show all 474)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM21262 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 15
2 COSM12945 TTBK1 lung,NS,carcinoma,large cell carcinoma c.2417C>T p.S806F 15
3 COSM12943 TRRAP lung,NS,carcinoma,large cell carcinoma c.8015C>T p.P2672L 15
4 COSM12942 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3021G>C p.W1007C 15
5 COSM43963 TP53 lung,NS,carcinoma,large cell carcinoma c.396G>C p.K132N 15
6 COSM44633 TP53 lung,NS,carcinoma,large cell carcinoma c.583A>T p.I195F 15
7 COSM10779 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>T p.R273L 15
8 COSM10733 TP53 lung,NS,carcinoma,large cell carcinoma c.574C>T p.Q192* 15
9 COSM10646 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>A p.C242Y 15
10 COSM10654 TP53 lung,NS,carcinoma,large cell carcinoma c.637C>T p.R213* 15
11 COSM43947 TP53 lung,NS,carcinoma,large cell carcinoma c.614A>G p.Y205C 15
12 COSM43896 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>C p.R273P 15
13 COSM44891 TP53 lung,NS,carcinoma,large cell carcinoma c.796G>T p.G266* 15
14 COSM43626 TP53 lung,NS,carcinoma,large cell carcinoma c.475G>A p.A159T 15
15 COSM11188 TP53 lung,NS,carcinoma,large cell carcinoma c.412G>C p.A138P 15
16 COSM45351 TP53 lung,NS,carcinoma,large cell carcinoma c.434T>G p.L145R 15
17 COSM43559 TP53 lung,NS,carcinoma,large cell carcinoma c.517G>T p.V173L 15
18 COSM11392 TP53 lung,NS,carcinoma,large cell carcinoma c.800G>C p.R267P 15
19 COSM10659 TP53 lung,NS,carcinoma,large cell carcinoma c.817C>T p.R273C 15
20 COSM6932 TP53 lung,NS,carcinoma,large cell carcinoma c.733G>A p.G245S 15
21 COSM10788 TP53 lung,NS,carcinoma,large cell carcinoma c.764T>G p.I255S 15
22 COSM44623 TP53 lung,NS,carcinoma,large cell carcinoma c.487T>A p.Y163N 15
23 COSM10648 TP53 lung,NS,carcinoma,large cell carcinoma c.524G>A p.R175H 15
24 COSM44621 TP53 lung,NS,carcinoma,large cell carcinoma c.718A>T p.S240C 15
25 COSM11323 TP53 lung,NS,carcinoma,large cell carcinoma c.482C>A p.A161D 15
26 COSM10810 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>T p.C242F 15
27 COSM10887 TP53 lung,NS,carcinoma,large cell carcinoma c.833C>G p.P278R 15
28 COSM10889 TP53 lung,NS,carcinoma,large cell carcinoma c.536A>G p.H179R 15
29 COSM10687 TP53 lung,NS,carcinoma,large cell carcinoma c.527G>A p.C176Y 15
30 COSM44133 TP53 lung,NS,carcinoma,large cell carcinoma c.859G>T p.E287* 15
31 COSM45677 TP53 lung,NS,carcinoma,large cell carcinoma c.714T>A p.C238* 15
32 COSM44204 TP53 lung,NS,carcinoma,large cell carcinoma c.423C>G p.C141W 15
33 COSM45268 TP53 lung,NS,carcinoma,large cell carcinoma c.827C>A p.A276D 15
34 COSM11333 TP53 lung,NS,carcinoma,large cell carcinoma c.499C>T p.Q167* 15
35 COSM43812 TP53 lung,NS,carcinoma,large cell carcinoma c.277C>A p.L93M 15
36 COSM43779 TP53 lung,NS,carcinoma,large cell carcinoma c.589G>A p.V197M 15
37 COSM45675 TP53 lung,NS,carcinoma,large cell carcinoma c.673-1G>C p.? 15
38 COSM3849376 TP53 lung,NS,carcinoma,large cell carcinoma c.753C>G p.I251M 15
39 COSM10750 TP53 lung,NS,carcinoma,large cell carcinoma c.490A>T p.K164* 15
40 COSM11114 TP53 lung,NS,carcinoma,large cell carcinoma c.528C>G p.C176W 15
41 COSM21593 TP53 lung,NS,carcinoma,large cell carcinoma c.358A>T p.K120* 15
42 COSM21267 STK33 lung,NS,carcinoma,large cell carcinoma c.478C>G p.L160V 15
43 COSM21263 STK17B lung,NS,carcinoma,large cell carcinoma c.837-1G>T p.? 15
44 COSM12925 STK11 lung,NS,carcinoma,large cell carcinoma c.109C>T p.Q37* 15
45 COSM27280 STK11 lung,NS,carcinoma,large cell carcinoma c.595G>C p.E199Q 15
46 COSM29006 STK11 lung,NS,carcinoma,large cell carcinoma c.256C>G p.R86G 15
47 COSM12962 RPS6KA6 lung,NS,carcinoma,large cell carcinoma c.419A>G p.Y140C 15
48 COSM12910 ROS1 lung,NS,carcinoma,large cell carcinoma c.2595G>C p.Q865H 15
49 COSM5154 PTEN lung,NS,carcinoma,large cell carcinoma c.697C>T p.R233* 15
50 COSM775 PIK3CA lung,NS,carcinoma,large cell carcinoma c.3140A>G p.H1047R 15

Expression for Lung Large Cell Carcinoma

Search GEO for disease gene expression data for Lung Large Cell Carcinoma.

Pathways for Lung Large Cell Carcinoma

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 BTK DDR2 EPHA5 FGFR1 MTOR ROS1
2
Show member pathways
12.19 DDR2 EPHA5 FGFR1 MYO18B ROS1
3 11.17 BTK DDR2 EPHA5 FGFR1 ROS1

GO Terms for Lung Large Cell Carcinoma

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intracellular signal transduction GO:0035556 9.73 BRSK1 BTK CDC42BPB WNK3
2 protein phosphorylation GO:0006468 9.7 ANKK1 BRSK1 BTK CDC42BPB DDR2 EPHA5
3 protein autophosphorylation GO:0046777 9.65 BTK DDR2 FGFR1 MTOR WNK3
4 negative regulation of gene expression GO:0010629 9.63 FGFR1 NME1 ROS1
5 peptidyl-tyrosine phosphorylation GO:0018108 9.63 BTK DDR2 EPHA5 FGFR1 ROS1 TTN
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.62 BTK DDR2 EPHA5 ROS1
7 positive regulation of neuron projection development GO:0010976 9.58 FGFR1 MTOR NME1
8 cell maturation GO:0048469 9.48 BTK FGFR1
9 phosphorylation GO:0016310 9.44 ANKK1 BRSK1 BTK CDC42BPB DDR2 EPHA5
10 cardiac muscle fiber development GO:0048739 9.37 MYO18B TTN

Molecular functions related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.97 ANKK1 BRSK1 BTK CDC42BPB DDR2 EPHA5
2 protein serine/threonine kinase activity GO:0004674 9.88 ANKK1 BRSK1 CDC42BPB MTOR TTN WNK3
3 protein tyrosine kinase activity GO:0004713 9.8 BTK DDR2 EPHA5 FGFR1 ROS1 TTN
4 protein kinase binding GO:0019901 9.73 BRSK1 MTOR NME1 TTN
5 protein kinase activity GO:0004672 9.7 ANKK1 BRSK1 BTK CDC42BPB DDR2 EPHA5
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.67 DDR2 EPHA5 FGFR1 ROS1
7 magnesium ion binding GO:0000287 9.65 BRSK1 CDC42BPB NME1
8 gamma-tubulin binding GO:0043015 9.46 BRSK1 NME1
9 kinase activity GO:0016301 9.44 ANKK1 BRSK1 BTK CDC42BPB DDR2 EPHA5
10 transferase activity GO:0016740 10.03 ANKK1 BRSK1 BTK CDC42BPB DDR2 EPHA5

Sources for Lung Large Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....